干扰素α对ph阴性骨髓增殖性肿瘤患者血清JAK2、CALR基因表达的影响  

Effect of interferon-α on serum JAK2 and CALR gene expression in patients with ph-negative myeloproliferative tumors

作　　者：罗爽[1] 花京剩 LUO Shuang;HUA Jing-sheng(Department of Hematology and Oncology,Taizhou Municipal Hospital,Taizhou 318000,Zhejiang,China)

机构地区：[1]台州市立医院血液肿瘤内科

出　　处：《广东医学》2020年第1期86-90,共5页Guangdong Medical Journal

摘　　要：目的研究干扰素α对ph阴性骨髓增殖性肿瘤患者血清JAK2、CALR基因表达的影响。方法选取就诊的52例ph阴性骨髓增殖性肿瘤患者,按照随机数字表法分为对照组和干扰素α组各26例。对照组患者口服羟基脲进行治疗,干扰素α组患者给予干扰素α-2b治疗。荧光定量检测JAK2、CALR基因突变,流式细胞仪检测外周血血细胞,进行临床症状评分,统计治疗总有效率、并发症发生率。结果两组患者治疗后JAK2、CALR基因突变比低于治疗前(P<0.05),干扰素α组治疗后JAK2、CALR基因突变比表达低于对照组治疗后(P<0.05)。两组患者治疗后白细胞、血红蛋白、血小板计数低于治疗前(P<0.05),干扰素α组治疗后白细胞、血红蛋白、血小板计数低于对照组治疗后(P<0.05)。两组患者治疗后临床症状评分低于治疗前(P<0.05),干扰素α组治疗后临床症状评分低于对照组治疗后(P<0.05)。干扰素α组患者治疗总有效率为84.62%,高于对照组患者的53.85%(P<0.05)。干扰素α组患者并发症发生率为7.69%,低于对照组患者的30.77%(P<0.05)。结论干扰素α对ph阴性骨髓增殖性肿瘤患者治疗效果显著,降低JAK2、CALR基因突变比,改善患者临床症状,减少患者并发症发生,临床治疗较为安全。Objective To study the effect of interferon-α on serum JAK2 and CALR gene expression in patients with ph-negative myeloproliferative tumors.Methods Fifty-two patients with ph-negative myeloproliferative tumors treated in our hospital from August 2016 to August 2018 were selected. The patients were randomly divided into control group and interferon-α group(n=26). The control group was treated with hydroxyurea, and the interferon-α group was treated with IFN-α 2 b. JAK2 and CALR gene mutation were quantitatively assessed by fluorescence. Peripheral blood cells were detected by flow cytometry. And clinical symptoms were scored. The total effective rate and incidence of complications were analyzed. Results The mutation ratio of JAK2 and CALR gene in two groups after treatment was significantly lower than that before treatment(P<0.05), and the mutation ratio of JAK2 and CALR gene in interferon-alpha group was significantly lower than that in control group after treatment(P<0.05). Leukocyte, hemoglobin and platelet counts in two groups after treatment were significantly lower than those before treatment(P<0.05). Leukocyte, hemoglobin and platelet counts in interferon-α group were significantly lower than those in control group after treatment(P<0.05). After treatment, the clinical symptom scores of the two groups were significantly lower than those before treatment(P<0.05), and that of the interferon-α group was significantly lower than that of the control group(P<0.05). The total effective rate of interferon-α group was 84.62%, which was significantly higher than that of the control group(53.85%, P<0.05). The incidence of complications in interferon-α group was 7.69%, significantly lower than that in control group(30.77%, P<0.05).Conclusion IFN-α has a significant therapeutic effect on patients with ph-negative myeloproliferative tumors. It promotes the expression of JAK2 and CALR genes, improves the clinical symptoms of patients, reduces the incidence of complications, and is safe for clinical treatment.

关 键 词：干扰素Α 骨髓增殖性肿瘤 JAK2 CALR 临床症状 

分 类 号：R733.3[医药卫生—肿瘤] R45[医药卫生—临床医学]